Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by assessing the 12-month EFS rate
Neoadjuvant Chemotherapy|Resectable Pancreatic Cancer
DRUG: irinotecan liposome + oxaliplatin + 5-FU / LV|DRUG: Adebellizumab
12-month EFS rate, the proportion of subjects with EFS events within one year., Up to 2 years.
Overall Survival, Defined as the time from random to death from any cause, Up to 2 years.|Event free survival, Defined as the time from randomization to disease progression, disease recurrence or death from any cause., Up to 2 years.|Disease free survival, Defined as the time from randomization to disease recurrence or death from any cause., Up to 2 years.|Objective response rate, Evaluation of the ORR by the investigator per RECIST v1.1 criteria means the proportion of subjects with the best overall efficacy of CR or PR. If the efficacy reaches CR and PR, the subject must be reviewed 4 weeks after the initial evaluation., Up to 2 years.|R0 resection rate, Defined as the proportion of subjects assessed as R0 resection., Up to 2 years.|Incidence of Treatment-Emergent Adverse Events, Incidence of Adverse events (AEs) / serious adverse events (SAEs) (as per NCI-CTCAE 5.0), Up to 2 years.
For patients with surgically resectable pancreatic cancer who have not received any anti-tumor therapy. To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by assessing the 12-month EFS rate.